For longer storage, freeze single-use aliquots at minus 20C and avoid repeated freeze-thaw cycles, which break the molecule down
Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, has demonstrated even more impressive effects, normalizing liver fat in about 90% of patients after 48 weeks of treatment
A randomised clinical trial, however, reported a slightly higher usage of liraglutide (30%) compared to the current study (21.1%), possibly due to differences in the availability or timeframe of these therapies [23]
Most studies have recognized that older age, longer DM duration, and worse glucose control are risk factors for DP
Established safety data from long-term supplementation studies